ADVA
6.10.2020 09:02:14 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced the general availability of its Ensemble Activator , the market’s first carrier-grade network operating system (NOS) designed for disaggregated cell site gateways (DCSGs). Already successful in trials with multiple global mobile network operators (MNOs) including Telefónica and Vodafone, Ensemble Activator disaggregates hardware from software, giving customers new levels of agility and freedom. Developed as part of the Telecom Infra Project (TIP), the feature-rich software enables MNOs to move away from closed proprietary systems and build open, vendor-neutral transport infrastructure with best-of-breed components. Now ready for commercial deployment in mobile networks, it offers MNOs a clear route to cost-effective mass rollout of 5G services.
“Today’s announcement marks the start of a new age of disaggregated mobile networks. By deploying our Ensemble Activator, MNOs will be able to leverage the full benefits of separated software and hardware and inject unprecedented speed, efficiency and flexibility into their transport infrastructure,” said Eli Angel, VP, product line management, Ethernet access, ADVA. “Built on our team’s vast experience equipping the largest public networks with the most advanced connectivity solutions, Ensemble Activator has now proven itself in a wide range of real-life scenarios. These include 5G field trials where Ensemble Activator combined with third-party white box hardware to create an open and cohesive DCSG solution . By turning cost-effective bare-metal switches into powerful packet network devices, it will equip MNOs to build tomorrow’s mobile infrastructure.”
Engineered through the TIP Disaggregated Cell Site Gateway group, ADVA’s Ensemble Activator is optimized for the operation of large, geographically dispersed networks. Proven in multiple tests with third-party hardware from suppliers such as Alpha Networks, Delta and Edgecore, it integrates seamlessly into existing management and control systems. With its carrier-class capabilities, Ensemble Activator offers a way to grow mobile networks that combines the agility of software-based feature development with the performance and cost-efficiency of bare-metal switches. Its comprehensive set of CE 2.0- and MEF 3.0-compliant interfaces is complemented with proven IP and MPLS protocols. What’s more, with its open control interfaces and telemetry streaming, Ensemble Activator is a significant step towards automated and eventually autonomous operations.
“Supporting the disaggregation of hardware and software while meeting the performance needs of the most demanding mobile networks is critical in transitioning today’s technology to open, highly scalable mobile transport architectures and enabling the mass rollout of 5G services. We are very excited about ADVA’s Ensemble Activator, as it offers something new to the market and enables a strong ecosystem for DCSG technology,” commented Luis MartinGarcia, manager, network technologies, Facebook and co-chair, DCSG group, TIP. “TIP is all about unleashing the power of collaboration and open innovation, and ADVA’s work demonstrates how quickly we build together in TIP to bring a powerful new technology to maturity.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005045/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom